EXACT Historical Income Statement

EXAS Stock

USD 53.01 0.29 0.54%

Historical analysis of EXACT Sciences income statement accounts such as Research Development of 452.8 M or Total Operating Expenses of 3.1 B can show how well EXACT Sciences performed in making a profits. Evaluating EXACT Sciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of EXACT Sciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining EXACT Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether EXACT Sciences is a good buy for the upcoming year.

Net Income Gross Profit

Build AI portfolio with EXACT Stock

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.

About EXACT Income Statement Analysis

EXACT Sciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to EXACT Sciences shareholders. The income statement also shows EXACT investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

EXACT Sciences Income Statement Chart

At this time, EXACT Sciences' Cost Of Revenue is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 13.2 M in 2025, despite the fact that EBIT is likely to grow to (953.4 M).

Research Development Total Operating Expenses Selling General Administrative Net Income Applicable To Common Shares

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from EXACT Sciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into EXACT Sciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.At this time, EXACT Sciences' Cost Of Revenue is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 13.2 M in 2025, despite the fact that EBIT is likely to grow to (953.4 M).

	2022	2024	2025 (projected)
Non Recurring	16.0M	14.4M	13.7M
Reconciled Depreciation	197.6M	214.9M	144.6M

Non Recurring Reconciled Depreciation

EXACT Sciences income statement Correlations

	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Tax Provision	Reconciled Depreciation	Non Recurring
Interest Expense		0.53	-0.45	-0.57	0.67	-0.55	0.51	-0.55	-0.25	0.52	0.41	0.5	0.51	0.43	-0.57	-0.6	0.53	-0.55	0.17	0.73	-0.99	-0.26	0.5	-0.14
Other Operating Expenses	0.53		-0.88	-0.87	0.95	-0.77	0.99	-0.86	-0.26	0.99	0.92	0.99	0.99	0.97	-0.88	-0.09	0.91	-0.86	-0.36	0.94	-0.59	-0.27	0.96	-0.91
Operating Income	-0.45	-0.88		0.98	-0.83	0.96	-0.93	0.96	0.3	-0.87	-0.66	-0.87	-0.85	-0.88	0.98	0.02	-0.96	0.96	0.27	-0.82	0.5	0.31	-0.81	0.79
Ebit	-0.57	-0.87	0.98		-0.87	0.98	-0.91	0.98	0.3	-0.87	-0.63	-0.84	-0.83	-0.84	1.0	0.18	-0.96	0.98	0.21	-0.83	0.61	0.3	-0.81	0.71
Research Development	0.67	0.95	-0.83	-0.87		-0.78	0.93	-0.88	-0.19	0.97	0.86	0.92	0.93	0.89	-0.88	-0.29	0.85	-0.87	-0.33	0.9	-0.71	-0.2	0.95	-0.77
Ebitda	-0.55	-0.77	0.96	0.98	-0.78		-0.83	0.96	0.3	-0.76	-0.49	-0.74	-0.73	-0.75	0.98	0.17	-0.92	0.96	0.14	-0.74	0.58	0.3	-0.7	0.6
Total Operating Expenses	0.51	0.99	-0.93	-0.91	0.93	-0.83		-0.9	-0.22	0.97	0.88	0.99	0.99	0.99	-0.92	-0.04	0.92	-0.9	-0.4	0.92	-0.57	-0.24	0.93	-0.9
Net Income	-0.55	-0.86	0.96	0.98	-0.88	0.96	-0.9		0.09	-0.86	-0.62	-0.84	-0.83	-0.85	0.98	0.17	-0.92	1.0	0.37	-0.79	0.59	0.1	-0.81	0.7
Income Tax Expense	-0.25	-0.26	0.3	0.3	-0.19	0.3	-0.22	0.09		-0.24	-0.23	-0.17	-0.18	-0.12	0.27	0.09	-0.37	0.09	-0.67	-0.38	0.25	1.0	-0.22	0.21
Depreciation And Amortization	0.52	0.99	-0.87	-0.87	0.97	-0.76	0.97	-0.86	-0.24		0.91	0.97	0.97	0.94	-0.87	-0.16	0.9	-0.86	-0.38	0.91	-0.57	-0.25	0.98	-0.9
Selling General Administrative	0.41	0.92	-0.66	-0.63	0.86	-0.49	0.88	-0.62	-0.23	0.91		0.93	0.94	0.89	-0.64	0.03	0.69	-0.62	-0.38	0.85	-0.48	-0.24	0.92	-0.89
Total Revenue	0.5	0.99	-0.87	-0.84	0.92	-0.74	0.99	-0.84	-0.17	0.97	0.93		1.0	0.99	-0.85	-0.03	0.87	-0.84	-0.46	0.92	-0.57	-0.18	0.94	-0.91
Gross Profit	0.51	0.99	-0.85	-0.83	0.93	-0.73	0.99	-0.83	-0.18	0.97	0.94	1.0		0.99	-0.84	-0.05	0.86	-0.83	-0.44	0.93	-0.58	-0.2	0.95	-0.91
Cost Of Revenue	0.43	0.97	-0.88	-0.84	0.89	-0.75	0.99	-0.85	-0.12	0.94	0.89	0.99	0.99		-0.85	0.03	0.86	-0.85	-0.51	0.89	-0.51	-0.13	0.91	-0.92
Income Before Tax	-0.57	-0.88	0.98	1.0	-0.88	0.98	-0.92	0.98	0.27	-0.87	-0.64	-0.85	-0.84	-0.85		0.16	-0.96	0.98	0.24	-0.83	0.61	0.28	-0.81	0.72
Total Other Income Expense Net	-0.6	-0.09	0.02	0.18	-0.29	0.17	-0.04	0.17	0.09	-0.16	0.03	-0.03	-0.05	0.03	0.16		-0.17	0.17	-0.09	-0.21	0.54	0.09	-0.17	-0.19
Selling And Marketing Expenses	0.53	0.91	-0.96	-0.96	0.85	-0.92	0.92	-0.92	-0.37	0.9	0.69	0.87	0.86	0.86	-0.96	-0.17		-0.92	-0.19	0.88	-0.57	-0.38	0.83	-0.79
Net Income From Continuing Ops	-0.55	-0.86	0.96	0.98	-0.87	0.96	-0.9	1.0	0.09	-0.86	-0.62	-0.84	-0.83	-0.85	0.98	0.17	-0.92		0.37	-0.79	0.59	0.1	-0.81	0.7
Non Operating Income Net Other	0.17	-0.36	0.27	0.21	-0.33	0.14	-0.4	0.37	-0.67	-0.38	-0.38	-0.46	-0.44	-0.51	0.24	-0.09	-0.19	0.37		-0.14	-0.11	-0.67	-0.39	0.48
Interest Income	0.73	0.94	-0.82	-0.83	0.9	-0.74	0.92	-0.79	-0.38	0.91	0.85	0.92	0.93	0.89	-0.83	-0.21	0.88	-0.79	-0.14		-0.78	-0.4	0.87	-0.76
Net Interest Income	-0.99	-0.59	0.5	0.61	-0.71	0.58	-0.57	0.59	0.25	-0.57	-0.48	-0.57	-0.58	-0.51	0.61	0.54	-0.57	0.59	-0.11	-0.78		0.26	-0.55	0.22
Tax Provision	-0.26	-0.27	0.31	0.3	-0.2	0.3	-0.24	0.1	1.0	-0.25	-0.24	-0.18	-0.2	-0.13	0.28	0.09	-0.38	0.1	-0.67	-0.4	0.26		-0.23	0.22
Reconciled Depreciation	0.5	0.96	-0.81	-0.81	0.95	-0.7	0.93	-0.81	-0.22	0.98	0.92	0.94	0.95	0.91	-0.81	-0.17	0.83	-0.81	-0.39	0.87	-0.55	-0.23		-0.89
Non Recurring	-0.14	-0.91	0.79	0.71	-0.77	0.6	-0.9	0.7	0.21	-0.9	-0.89	-0.91	-0.91	-0.92	0.72	-0.19	-0.79	0.7	0.48	-0.76	0.22	0.22	-0.89

Click cells to compare fundamentals

EXACT Sciences Account Relationship Matchups

EXACT Sciences income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	96.0M	18.6M	19.6M	24.4M	32.0M	33.6M
Other Operating Expenses	2.0B	2.6B	2.7B	2.7B	3.0B	3.1B
Operating Income	(558.4M)	(835.5M)	(577.5M)	(215.0M)	(1.0B)	(996.3M)
Ebit	(811.9M)	(823.9M)	(612.9M)	(164.7M)	(1.0B)	(953.4M)
Research Development	554.1M	385.6M	393.4M	425.9M	431.2M	452.8M
Ebitda	(632.9M)	(617.7M)	(386.7M)	41.9M	(788.7M)	(749.3M)
Total Operating Expenses	1.7B	2.1B	2.1B	2.1B	3.0B	3.1B
Net Income	(848.5M)	(595.6M)	(623.5M)	(204.1M)	(1.0B)	(977.4M)
Income Tax Expense	(8.6M)	(246.9M)	(9.1M)	2.4M	(7.3M)	(6.9M)
Depreciation And Amortization	179.1M	206.2M	226.2M	206.6M	214.9M	225.6M
Selling General Administrative	481.7M	801.3M	737.3M	1.4B	781.8M	820.9M
Total Revenue	1.5B	1.8B	2.1B	2.5B	2.8B	2.9B
Gross Profit	1.1B	1.3B	1.5B	1.8B	1.9B	2.0B
Cost Of Revenue	354.3M	458.8M	574.4M	654.2M	840.2M	882.2M
Income Before Tax	(857.1M)	(842.5M)	(632.6M)	(201.7M)	(1.0B)	(1.1B)
Total Other Income Expense Net	(61.4M)	13.2M	(39.1M)	13.3M	12.5M	13.2M
Selling And Marketing Expenses	589.9M	861.9M	846.0M	203.9M	894.1M	938.8M
Net Income From Continuing Ops	(848.5M)	(595.6M)	(623.5M)	(204.1M)	(1.0B)	(977.4M)
Non Operating Income Net Other	26.5M	6.9M	31.8M	(19.4M)	(22.3M)	(21.2M)
Net Income Applicable To Common Shares	(84.0M)	(848.5M)	(595.6M)	(623.5M)	(561.2M)	(533.1M)
Net Interest Income	(88.0M)	(18.6M)	(19.6M)	(29.8M)	(37.3M)	(39.1M)
Tax Provision	(8.6M)	(246.9M)	(9.1M)	2.4M	(7.3M)	(7.7M)
Reconciled Depreciation	163.4M	180.3M	197.6M	206.6M	214.9M	144.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for EXACT Stock Analysis

When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

EXACT Historical Income Statement

About EXACT Income Statement Analysis

EXACT Sciences Income Statement Chart

Total Operating Expenses

Net Income Applicable To Common Shares

EXACT Sciences income statement Correlations

EXACT Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

EXACT Sciences income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for EXACT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Before Tax	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Tax Provision	+ 1.0	Income Tax Expense
Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 0.99	Other Operating Expenses
Depreciation And Amortization	+ 0.99	Other Operating Expenses

Net Interest Income	- 0.99	Interest Expense
Selling And Marketing Expenses	- 0.96	Income Before Tax
Selling And Marketing Expenses	- 0.96	Ebit
Selling And Marketing Expenses	- 0.96	Operating Income
Total Operating Expenses	- 0.93	Operating Income
Net Income From Continuing Ops	- 0.92	Selling And Marketing Expenses